Invention Grant
- Patent Title: Mutant interferon α protein and use thereof
- Patent Title (中): 突变型干扰素α蛋白及其用途
-
Application No.: US11719283Application Date: 2005-11-09
-
Publication No.: US07666403B2Publication Date: 2010-02-23
- Inventor: Tadanori Mayumi , Yasuo Tsutsumi , Shinsaku Nakagawa , Madoka Taniai , Kakuji Torigoe , Masashi Kurimoto
- Applicant: Tadanori Mayumi , Yasuo Tsutsumi , Shinsaku Nakagawa , Madoka Taniai , Kakuji Torigoe , Masashi Kurimoto
- Applicant Address: JP Okayama JP Hyogo JP Osaka JP Osaka
- Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo,Tadanori Mayumi,Yasuo Tsutsumi,Shinsaku Nakagawa
- Current Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo,Tadanori Mayumi,Yasuo Tsutsumi,Shinsaku Nakagawa
- Current Assignee Address: JP Okayama JP Hyogo JP Osaka JP Osaka
- Agency: Browdy and Neimark, PLLC
- Priority: JP2004-329461 20041112
- International Application: PCT/JP2005/020514 WO 20051109
- International Announcement: WO2006/051805 WO 20060518
- Main IPC: C07K14/52
- IPC: C07K14/52 ; C12N15/21 ; A61K38/21

Abstract:
The present invention has objects to provide a mutant interferon-α protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-α protein as an effective ingredient; and solves the above objects by providing a mutant protein which has an amino acid sequence of human interferon-α subtype α8 represented by any one of SEQ ID NOs:1 to 3, where the arginine residue at the 145th has been replaced with leucine, isoleucine, or valine residue; the alanine residue at the 146th has been replaced with asparagine or serine residue; and the methionine residue at the 149th has been replaced with tyrosine residue; and an agent for susceptive diseases, containing the mutant protein.
Public/Granted literature
- US20090311218A1 mutant interferon alpha protein and use thereof Public/Granted day:2009-12-17
Information query